Next Generation Sequencing (NGS) Kits Market: Distribution by Type of Nucleotide Sequenced (DNA and RNA), Type of End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Others) and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2022

  • Pages
    218

  • View Count
    3277

Example Insights

Next-Generation-Sequencing-Kits-Market-Context Next-Generation-Sequencing-Kits-Market-List-of-NGS Next-Generation-Sequencing-Kits-Market-Next-Generation-Sequencing
Next-Generation-Sequencing-Kits-Market-Kit-Providers Next-Generation-Sequencing-Kits-Market-Competitiveness-Analysis Next-Generation-Sequencing-Kits-Market-Type-of-Patent
Next-Generation-Sequencing-Kits-Market-Industry-Players Next-Generation-Sequencing-Kits-Market-Growth-Scenarios  

 

Overview

The field of genomic data collection and analysis has evolved significantly since the introduction of a gene sequencing method by Frederick Sanger in 1977. Advances in DNA sequencing technologies have led to significant developments in a variety of healthcare-focused research fields, such as precision medicine and diagnostics. Particularly, the impact of next generation sequencing (NGS) methods, enabling whole genome and whole exome sequencing, has been the most profound. This high throughput, parallel genome sequencing technology has greatly reduced the overall cost and time investment. In fact, compared to the Human Genome Project (~USD 3 billion), the cost of sequencing a single genome has decreased considerably (to USD 1,000), for currently available technologies. Given the ongoing innovation in this field, stakeholders further believe that, over the next decade, the aforementioned cost may further get reduced to USD 100. It is worth mentioning that this decrease in genome sequencing cost has led to an increase in the number of genomes being sequenced, across the globe. 

Despite the recent advances in the field of genomics, the nucleotide library preparation process is still marred with several challenges, including requirement of large amounts of input samples, low volume of yield and concerns related to quality of the product. In addition, the manual DNA library / RNA library preparation process is time consuming, requiring extensive manipulation and expensive reagents. Therefore, innovators in the pharmaceutical industry are constantly identifying / developing ways to improve the process of DNA library / RNA library preparation. Amidst other alternatives, the use of NGS library preparation kits has emerged as a viable option for various drug developers and academic / research institutes to overcome the existing challenges associated with conventional DNA library / RNA library preparation methods. These kits require less input material and are capable of generating precise DNA library / RNA libraries with minimum errors. Presently, more than 280 NGS library preparation kits are available in the market; these are compatible with a broad range of sequencing platforms, including Illumina®, Ion Torrent® and BGI NGS platforms. It is worth mentioning that over 3,200 patents related to NGS library preparation kits have been filed / granted in the past few years, demonstrating the continued innovation in this domain. Driven by the increasing demand for gene therapies and the introduction of novel and advanced NGS techniques, the NGS library preparation kits market is anticipated to witness steady growth in the coming years.

Scope of the Report

The “Next Generation Sequencing (NGS) Kits Market: Distribution by Type of Nucleotide Sequenced (DNA and RNA), Type of End User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Hospitals and Clinics, and Others) and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of NGS library preparation kits over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of NGS library preparation kits, featuring information on the type of nucleotide sequenced (DNA and RNA), kit components (control total RNA / DNA, adapters, primers, enzyme mixes, buffers, RNA / DNA probes and others), quantity of sample required (less than 5 ng, 5 ng to 10 ng and more than 10 ng), turnaround time (less than 5 hours, 5 hours to 10 hours and more than 10 hours), storage temperature (deep freeze, cold and room temperature), type of sample used (purified RNA / DNA, plasma, serum, urine, cells, blood, saliva and others), kit shelf life (0.5 year and 1 year), type of sequencing (whole genome sequencing, targeted sequencing, transcriptome sequencing, RNA sequencing, ChIP sequencing, exome sequencing, bisulphite sequencing, methyl sequencing,  amplicon sequencing, de novo sequencing, resequencing and shotgun sequencing) and type of sequencing platform used (Illumina, BGI, Ion Torrent, Fluidigm and Oxford Nanopore Technologies). In addition, the chapter features analysis related to NGS library preparation kit providers based on parameters, such as year of establishment, company size, location of headquarters and leading players (in terms of number of products). 
  • A competitiveness analysis of NGS library preparation kits based on various relevant parameters, namely supplier power (based on the experience of the developer) and product competitiveness (based on parameters, including type of nucleotide sequenced, kit components, quantity of sample required, turnaround time, type of sample used, kit shelf life, type of sequencing and type of sequencing platform used).
  • Elaborate profiles of prominent players offering NGS library preparation kits, based in North America, Europe and Asia Pacific. Each profile features a brief overview of the company, details related to its financials (if available), product portfolio, recent developments and an informed future outlook.
  • An in-depth analysis of the various patents that have been filed / granted related to NGS library preparation kits and reagents, from January 2020 to October 2021, taking into consideration parameters, such as publication year, geographical region, CPC symbols, patent focus areas, type of applicant and leading players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • A case study on the history and evolution of genome sequencing with details on first, second and third generation sequencing platforms. The chapter includes information on the NGS technologies that are available till date. Further, it presents information on the various NGS service providers (industry and non-industry players) that are engaged in providing whole genome, whole exome and targeted sequencing services.  

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for NGS library preparation kits over the coming decade. We have provided an informed estimate on the likely evolution of the market over the period 2021-2035. The report features sales forecasts for the overall NGS library preparation kits market, wherein both the current and upcoming opportunity is segmented across [A] type of nucleotide sequenced (DNA and RNA), [B] type of end user (academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, and others) and [C] key geographies (North America, Europe, Asia Pacific, Middle East and North Africa, Latin America and Rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Key Questions Answered

  • Who are the key players engaged in offering NGS library preparation kits?
  • What is the relative competitiveness of different NGS library preparation kits?
  • How is the intellectual property landscape for next generation sequencing kits likely to evolve in the foreseen future?
  • What are the factors that are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our report. It offers a high-level view of the current state of NGS library preparation kits market and its likely evolution in the short term, mid-term, and long term.

Chapter 3 provides a general overview of genome sequencing and its different types, including whole genome sequencing, whole exome sequencing, targeted sequencing, epigenetics, metagenomics and RNA sequencing. Further, the chapter features an elaborate discussion on NGS, along with its advantages and applications in the pharmaceutical industry. Furthermore, it provides information on the various steps involved in NGS procedure. The chapter also includes the NGS kit components that are currently available in the market.

Chapter 4 provides a comprehensive review of the current market landscape of NGS library preparation kits, featuring information on the type of nucleotide sequenced (DNA and RNA), kit components (control total RNA / DNA, adapters, primers, enzyme mixes, buffers, RNA / DNA probes and others), quantity of sample required (less than 5 ng, 5 ng to 10 ng and more than 10 ng), turnaround time (less than 5 hours, 5 hours to 10 hours and more than 10 hours), storage temperature (deep freeze, cold and room temperature), type of sample used (purified RNA / DNA, plasma, serum, urine, cells, blood, saliva and others), kit shelf life (0.5 year and 1 year), type of sequencing (whole genome sequencing, targeted sequencing, transcriptome sequencing, RNA sequencing, ChIP sequencing, exome sequencing, bisulphite sequencing, methyl sequencing,  amplicon sequencing, de novo sequencing, resequencing and shotgun sequencing) and type of sequencing platform used (Illumina, BGI, Ion Torrent, Fluidigm and Oxford Nanopore Technologies). In addition, the chapter features analysis related to NGS library preparation kit providers, based on parameters, such as year of establishment, company size, location of headquarters and leading players (in terms of number of products).

Chapter 5 presents a detailed competitiveness analysis of NGS library preparation kits, based on various relevant parameters, namely supplier power (based on the experience of the developer) and product competitiveness (based on parameters, including type of nucleotide sequenced, kit components, quantity of sample required, turnaround time, type of sample used, kit shelf life, type of sequencing and type of sequencing platform used). 

Chapter 6 features detailed profiles of the prominent companies that offer NGS library preparation kits in North America. Each company profile features a brief overview of the company, details related to its financials (if available), NGS kit portfolio, recent developments and an informed future outlook. 

Chapter 7 features detailed profiles of the prominent companies that offer NGS library preparation kits in Europe. Each company profile features a brief overview of the company, details related to its financials (if available), NGS kit portfolio, recent developments and an informed future outlook. 

Chapter 8 features detailed profiles of the prominent companies that offer NGS library preparation kits in Asia Pacific. Each company profile features a brief overview of the company, details related to its financials (if available), NGS kit portfolio, recent developments and an informed future outlook. 

Chapter 9 provides an in-depth patent analysis to provide an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered those patents that have been filed / granted related to NGS library preparation kits and reagents, from January 2020 to October 2021, taking into consideration parameters, such as publication year, geographical region, CPC symbols, patent focus areas, type of applicant and leading industry players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis. 

Chapter 10 presents a comprehensive market forecast analysis, highlighting the future potential of the market till 2035. We have segregated the current and upcoming opportunity based on [A] type of nucleotide sequenced (DNA and RNA), [B] type of end user (academic and research institutes, pharmaceutical and biotechnology companies, hospitals and clinics, and others) and [C] key geographies (North America, Europe, Asia Pacific, Middle East and North Africa, Latin America and Rest of the world). It is worth mentioning that we adopted a top-down approach for this analysis, backing our claims with relevant datapoints and credible inputs from primary research. 

Chapter 11 presents a detailed case study on the history and evolution of genome sequencing with details on first, second and third generation sequencing platforms. The chapter includes information on the NGS technologies that are available till date. Further, it presents information on the various NGS service providers (industry and non-industry players) that are engaged in providing whole genome, whole exome and targeted sequencing services. 

Chapter 12 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interview held with Len Goren (General Manager, Tecan). 

Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 15 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3 Introduction
3.1. Chapter Overview
3.2. Overview of Genome Sequencing
3.3. Types of Genome Sequencing
3.3.1. Next Generation Sequencing
3.3.1.1. Applications of Next Generation Sequencing
3.3.1.1.1. Cancer and Affiliated Biomarker Research
3.3.1.1.2. Diagnostics
3.3.1.1.3. Personalized / Precision Medicine
3.3.1.1.4. Forensics

3.3.1.2. Steps Involved in Next Generation Sequencing
3.3.1.2.1. Library Preparation
3.3.1.2.2. Amplification
3.3.1.2.3. Sequencing
3.3.1.2.4. Bioinformatics Analysis and Data Interpretation
3.3.1.3. Components of Next Generation Sequencing Kits
3.4. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Next Generation Sequencing Kits: Overall Market Landscape
4.2.1. Analysis by Type of Nucleotide Sequenced
4.2.2. Analysis by Kit Components
4.2.3. Analysis by Quantity of Sample Required
4.2.4. Analysis by Turnaround Time
4.2.5. Analysis by Storage Temperature
4.2.6. Analysis by Type of Sample Used
4.2.7. Analysis by Kit Shelf Life
4.2.8. Analysis by Type of Sequencing
4.2.9. Analysis by Type of Sequencing Platform Used
 
4.3. Next Generation Sequencing Kits: List of Providers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Players: Analysis by Number of Products

5. PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Methodology
5.3. Product Competitiveness Analysis: Competitive Landscape

6. COMPANY PROFILES: NEXT GENERATION SEQUENCING KITS PROVIDERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. Agilent Technologies
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. NGS Kit Portfolio
6.2.4. Recent Developments and Future Outlook
 
6.3. BioDynami
6.3.1. Company Overview
6.3.2. NGS Kit Portfolio
6.3.3. Recent Developments and Future Outlook
 
6.4. Creative Biogene
6.4.1. Company Overview
6.4.2. NGS Kit Portfolio
6.4.3. Recent Developments and Future Outlook
 
6.5. New England Biolabs
6.5.1. Company Overview
6.5.2. NGS Kit Portfolio
6.5.3. Recent Developments and Future Outlook
 
6.6. PerkinElmer
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. NGS Kit Portfolio
6.6.4. Recent Developments and Future Outlook
 
6.7. Thermo Fisher Scientific
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. NGS Kit Portfolio
6.7.4. Recent Developments and Future Outlook

7. COMPANY PROFILES: NEXT GENERATION SEQUENCING KITS PROVIDERS IN EUROPE
7.1. Chapter Overview
7.2. Abcam
7.2.1 Company Overview
7.2.2. Financial Information
7.2.3. NGS Kit Portfolio
7.2.4. Recent Developments and Future Outlook
 
7.3. Devyser
7.3.1 Company Overview
7.3.2. NGS Kit Portfolio
7.3.3. Recent Developments and Future Outlook
 
7.4. Diagenode
7.4.1 Company Overview
7.4.2. NGS Kit Portfolio
7.4.3. Recent Developments and Future Outlook
 
7.5. Lexogen
7.5.1 Company Overview
7.5.2. NGS Kit Portfolio
7.5.3. Recent Developments and Future Outlook
 
7.6. Roche
7.6.1 Company Overview
7.6.2. Financial Information
7.6.3. NGS Kit Portfolio
7.6.4. Recent Developments and Future Outlook
 
7.7. Tecan
7.7.1 Company Overview
7.7.2. Financial Information
7.7.3. NGS Kit Portfolio
7.7.4. Recent Developments and Future Outlook

8. COMPANY PROFILES: NEXT GENERATION SEQUENCING KITS PROVIDERS IN ASIA PACIFIC
8.1. Chapter Overview
8.2. Enzynomics
8.2.1. Company Overview
8.2.2. NGS Kit Portfolio
8.2.3. Recent Developments and Future Outlook
 
8.3. MGI
8.3.1. Company Overview
8.3.2. NGS Kit Portfolio
8.3.3. Recent Developments and Future Outlook
 
8.4. Takara Bio
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. NGS Kit Portfolio
8.4.4. Recent Developments and Future Outlook
 
8.5. TIANGEN Biotech
8.5.1. Company Overview
8.5.2. NGS Kit Portfolio
8.5.3. Recent Developments and Future Outlook
 
8.6. TransGen Biotech
8.6.1. Company Overview
8.6.2. NGS Kit Portfolio
8.6.3. Recent Developments and Future Outlook
 
8.7. Vazyme
8.7.1. Company Overview
8.7.2. NGS Kit Portfolio
8.7.3. Recent Developments and Future Outlook

9. PATENT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Next Generation Sequencing Kits: Patent Analysis
9.3.1 Analysis by Publication Year
9.3.2. Analysis by Geography
9.3.3. Analysis by CPC Symbols
9.3.4. Emerging Focus Areas
9.3.5. Analysis by Type of Applicant
9.3.6. Leading Players: Analysis by Number of Patents
 
9.4. Next Generation Sequencing Kits: Patent Benchmarking
9.4.1. Analysis by Patent Characteristics
9.5. Next Generation Sequencing Kits: Patent Valuation
9.6. Leading Patents: Analysis by Number of Citations

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Next Generation Sequencing Kits Market, 2021-2035
10.3.1. Next Generation Sequencing Kits Market, 2021 and 2035: Distribution by Type of Nucleotide Sequenced
10.3.1.1. Next Generation Sequencing Kits Market for DNA, 2021-2035
10.3.1.2. Next Generation Sequencing Market for RNA, 2021-2035
 
10.3.2. Next Generation Sequencing Kits Market, 2021 and 2035: Distribution by Type of End User
10.3.2.1. Next Generation Sequencing Kits Market for Academic and Research Institutes, 2021-2035
10.3.2.2. Next Generation Sequencing Kits Market for Pharmaceutical and Biotechnology Companies, 2021-2035
10.3.2.3. Next Generation Sequencing Kits Market for Hospitals and Clinics, 2021-2035
10.3.2.4. Next Generation Sequencing Kits Market for Others, 2021-2035
 
10.3.3. Next Generation Sequencing Kits Market, 2021 and 2035: Distribution by Geography
10.3.3.1. Next Generation Sequencing Kits Market in North America, 2021-2035
10.3.3.2. Next Generation Sequencing Kits Market in Europe, 2021-2035
10.3.3.3. Next Generation Sequencing Kits Market in Asia Pacific, 2021-2035
10.3.3.4. Next Generation Sequencing Kits Market in Middle East and North Africa, 2021-2035
10.3.3.5. Next Generation Sequencing Kits Market in Latin America, 2021-2035
10.3.3.6. Next Generation Sequencing Kits Market in Rest of the World, 2021-2035

11. CASE STUDY: NEXT GENERATION SEQUENCING TECHNOLOGIES AND SERVICE PROVIDERS
11.1. Chapter Overview
11.2. Historical Evolution of Genome Sequencing
11.2.1. First Generation DNA Sequencers
11.2.2. Second Generation HT-NGS Platforms
11.2.3. Third Generation HT-NGS Platforms
11.2.3.1. Heliscope Single Molecule Sequencer
11.2.3.2. Single Molecule Real Time Sequencer
11.2.3.3. Single Molecule Real Time (RNAP) Sequencer
11.2.3.4. Nanopore DNA Sequencer
11.2.3.5. Multiplex Polony Technology
11.2.3.6. The Ion Torrent Sequencing Technology
11.2.4. Comparison of First, Second and Third Generation technologies
 
11.3. Next Generation Sequencing Technologies
11.3.1. Analysis by Type of Application
 
11.4. Next Generation Sequencing Service Providers
11.4.1. Next Generation Sequencing Service Providers: Industry Players
11.4.2. Analysis by Year of Establishment
11.4.3. Analysis by Company Size
11.4.4. Analysis by Location of Headquarters
11.4.5. Analysis by Type of Service Offered
 
11.5. Next Generation Sequencing Service Providers: Non-Industry Players
11.5.1. Analysis by Year of Establishment
11.5.2. Analysis by Location of Headquarters
11.5.3. Analysis by Type of Service Offered

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Tecan
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Len Goren, General Manager

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Forecast
Figure 2.2 Executive Summary: Overall Market Landscape
Figure 2.3 Executive Summary: Patent Analysis
Figure 3.1 Types of Sequencing
Figure 3.2 Applications of Next Generation Sequencing
Figure 3.3 Steps Involved in Next Generation Sequencing
Figure 4.1 Next Generation Sequencing Kits: Distribution by Type of Nucleotide Sequenced
Figure 4.2 Next Generation Sequencing Kits: Distribution by Kit Components
Figure 4.3 Next Generation Sequencing Kits: Distribution by Quantity of Sample Required
Figure 4.4 Next Generation Sequencing Kits: Distribution by Turnaround Time
Figure 4.5 Next Generation Sequencing Kits: Distribution by Storage Temperature
Figure 4.6 Next Generation Sequencing Kits: Distribution by Type of Sample Used
Figure 4.7 Next Generation Sequencing Kits: Distribution by Kit Shelf Life
Figure 4.8 Next Generation Sequencing Kits: Distribution by Type of Sequencing
Figure 4.9 Next Generation Sequencing Kits: Distribution by Type of Sequencing Platform Used
Figure 4.10 Next Generation Sequencing Kit Providers: Distribution by Year of Establishment
Figure 4.11 Next Generation Sequencing Kit Providers: Distribution by Company Size
Figure 4.12 Next Generation Sequencing Kit Providers: Distribution by Location of Headquarters
Figure 4.13 Leading Players: Distribution by Number of Products
Figure 5.1 Next Generation Sequencing Kits: Dot Plot Analysis
Figure 5.2 Product Competitiveness Analysis: Competitive Landscape
Figure 6.1 Agilent Technologies: Annual Revenues, 2016-9M 2021 (USD Billion)
Figure 6.2 PerkinElmer: Annual Revenues, 2016-H1 2021 (USD Billion)
Figure 6.3 Thermo Fisher Scientific: Annual Revenues, 2016-H1 2021 (USD Billion)
Figure 7.1 Abcam: Annual Revenues, FY 2016-H1 2021 (GBP Million)
Figure 7.2 Roche: Annual Revenues, 2016-H1 2021 (CHF Billion)
Figure 7.3 Tecan: Annual Revenues, 2016-H1 2021 (CHF Million)
Figure 8.1 Takara Bio: Annual Revenues, FY 2016-Q1 2021 (JPY Billion)
Figure 9.1 Patent Analysis: Distribution by Type of Patent
Figure 9.2 Patent Analysis: Distribution by Year of Publication
Figure 9.3 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Figure 9.4 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Figure 9.5 Patent Analysis: Distribution by CPC Symbols
Figure 9.6 Patent Analysis: Emerging Focus Areas
Figure 9.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 9.8 Leading Industry Players: Distribution by Number of Patents
Figure 9.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 9.10 Leading Patent Assignees: Distribution by Number of Patents
Figure 9.11 Patent Benchmarking: Distribution of Leading Industry Player by Patent Characteristics (CPC Symbols)
Figure 9.12 Patent Analysis: Distribution by Age
Figure 9.13 Patent Analysis: Patent Valuation
Figure 10.1 Global Next Generation Sequencing Kits Market, 2021-2035 (USD Billion)
Figure 10.2 Next Generation Sequencing Kits: Likely Growth Scenarios
Figure 10.3 Next Generation Sequencing Kits Market: Distribution by Type of Nucleotide Sequenced, 2021 and 2035 (USD Billion)
Figure 10.4 Next Generation Sequencing Kits Market for DNA, 2021-2035 (USD Billion)
Figure 10.5 Next Generation Sequencing Market for RNA, 2021-2035 (USD Billion)
Figure 10.6 Next Generation Sequencing Kits Market: Distribution by Type of End User, 2021 and 2035 (USD Billion)
Figure 10.7 Next Generation Sequencing Kits Market for Academic and Research Institutes, 2021-2035 (USD Billion)
Figure 10.8 Next Generation Sequencing Kits Market for Pharmaceutical and Biotechnology Companies, 2021-2035 (USD Billion)
Figure 10.9 Next Generation Sequencing Kits Market for Hospitals and Clinics, 2021-2035 (USD Billion)
Figure 10.10 Next Generation Sequencing Kits Market for Others, 2021-2035 (USD Billion)
Figure 10.11 Next Generation Sequencing Kits: Distribution by Geography, 2021 and 2035 (USD Billion)
Figure 10.12 Next Generation Sequencing Kits Market in North America, 2021-2035 (USD Billion)
Figure 10.13 Next Generation Sequencing Kits Market in Europe, 2021-2035 (USD Billion)
Figure 10.14 Next Generation Sequencing Kits Market in Asia Pacific, 2021-2035 (USD Billion)
Figure 10.15 Next Generation Sequencing Kits Market in Middle East and North Africa, 2021-2035 (USD Billion)
Figure 10.16 Next Generation Sequencing Kits Market in Latin America, 2021-2035 (USD Billion)
Figure 10.17 Next Generation Sequencing Kits Market in Rest of the World, 2021-2035 (USD Billion)
Figure 11.1 Third Generation HT-NGS Platforms
Figure 11.2 Next Generation Sequencing Technologies: Analysis by Type of Application
Figure 11.3 Next Generation Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
Figure 11.4 Next Generation Sequencing Service Providers (Industry Players): Distribution by Company Size
Figure 11.5 Next Generation Sequencing Service Providers (Industry Players): Distribution by Location of Headquarters
Figure 11.6 Next Generation Sequencing Service Providers (Industry Players): Distribution by Type of Service Offered
Figure 11.7 Next Generation Sequencing Service Providers (Non-Industry Players): Distribution by Year of Establishment
Figure 11.8 Next Generation Sequencing Service Providers (Non-Industry Players): Distribution by Location of Headquarters
Figure 11.9 Next Generation Sequencing Service Providers (Non-Industry Players): Distribution by Type of Service Offered
Figure 12.1 Concluding Remarks: Overall Market Landscape
Figure 12.2 Concluding Remarks: Patent Analysis
Figure 12.3 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1 Next Generation Sequencing Kits: List of Products
Table 4.2 Next Generation Sequencing Kits: Information on Type of Sample Used, Kit Shelf Life, Type of Sequencing and Type of Sequencing Platform Used
Table 4.3 Next Generation Sequencing Kits: List of Providers
Table 6.1 Leading NGS Kit Providers in North America
Table 6.2 Agilent Technologies: Company Snapshot
Table 6.3 Agilent Technologies: NGS Kit Portfolio
Table 6.4 Agilent Technologies: Recent Developments and Future Outlook
Table 6.5 BioDynami: Company Snapshot
Table 6.6 BioDynami: NGS Kit Portfolio
Table 6.7 BioDynami: Recent Developments and Future Outlook
Table 6.8 Creative Biogene: Company Snapshot
Table 6.9 Creative Biogene: NGS Kit Portfolio
Table 6.10 Creative Biogene: Recent Developments and Future Outlook
Table 6.11 New England Biolabs: Company Snapshot
Table 6.12 New England Biolabs: NGS Kit Portfolio
Table 6.13 New England Biolabs: Recent Developments and Future Outlook
Table 6.14 PerkinElmer: Company Snapshot
Table 6.15 PerkinElmer: NGS Kit Portfolio
Table 6.16 PerkinElmer: Recent Developments and Future Outlook
Table 6.17 Thermo Fisher Scientific: Company Snapshot
Table 6.18 Thermo Fisher Scientific: NGS Kit Portfolio
Table 6.19 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 7.1 Leading NGS Kit Providers in Europe
Table 7.2 Abcam: Company Snapshot
Table 7.3 Abcam: NGS Kit Portfolio
Table 7.4 Abcam: Recent Developments and Future Outlook
Table 7.5 Devyser: Company Snapshot
Table 7.6 Devyser: NGS Kit Portfolio
Table 7.7 Devyser: Recent Developments and Future Outlook
Table 7.8 Diagenode: Company Snapshot
Table 7.9 Diagenode: NGS Kit Portfolio
Table 7.10 Diagenode: Recent Developments and Future Outlook
Table 7.11 Lexogen: Company Snapshot
Table 7.12 Lexogen: NGS Kit Portfolio
Table 7.13 Lexogen: Recent Developments and Future Outlook
Table 7.14 Roche: Company Snapshot
Table 7.15 Roche: NGS Kit Portfolio
Table 7.16 Roche: Recent Developments and Future Outlook
Table 7.17 Tecan: Company Snapshot
Table 7.18 Tecan: NGS Kit Portfolio
Table 7.19 Tecan: Recent Developments and Future Outlook
Table 8.1 Leading NGS Kit Providers in Asia Pacific
Table 8.2 Enzynomics: Company Snapshot
Table 8.3 Enzynomics: NGS Kit Portfolio
Table 8.4 MGI: Company Snapshot
Table 8.5 MGI: NGS Kit Portfolio
Table 8.6 Takara Bio: Company Snapshot
Table 8.7 Takara Bio: NGS Kit Portfolio
Table 8.8 Takara Bio: Recent Developments and Future Outlook
Table 8.9 TIANGEN Biotech: Company Snapshot
Table 8.10 TIANGEN Biotech: NGS Kit Portfolio
Table 8.11 TransGen Biotech: Company Snapshot
Table 8.12 TransGen Biotech: NGS Kit Portfolio
Table 8.13 Vazyme: Company Snapshot
Table 8.14 Vazyme: NGS Kit Portfolio
Table 9.1 Patent Analysis: Prominent CPC Symbols
Table 9.2 Patent Analysis: Most Popular CPC Symbols
Table 9.3 Patent Analysis: List of Top CPC Symbols
Table 9.4 Patent Analysis: Summary of Benchmarking Analysis
Table 9.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 9.6 Patent Portfolio: List of Leading Patents (in terms of Highest Relative Valuation)
Table 9.7 Patent Portfolio: List of Leading Patents (in terms of Number of Citations)
Table 11.1 Comparison of First, Second and Third Generation Sequencing Technologies
Table 11.2 Next Generation Sequencing: List of Available Technologies
Table 11.3 Next Generation Sequencing Service Providers: List of Industry Players
Table 11.4 Next Generation Sequencing Service Providers: List of Non-Industry Players
Table 13.1 Tecan: Company Snapshot
Table 14.1 Next Generation Sequencing Kits: Distribution by Type of Nucleotide Sequenced
Table 14.2 Next Generation Sequencing Kits: Distribution by Kit Components
Table 14.3 Next Generation Sequencing Kits: Distribution by Quantity of Sample Required
Table 14.4 Next Generation Sequencing Kits: Distribution by Turnaround Time
Table 14.5 Next Generation Sequencing Kits: Distribution by Storage Temperature
Table 14.6 Next Generation Sequencing Kits: Distribution by Type of Sample Used
Table 14.7 Next Generation Sequencing Kits: Distribution by Kit Shelf Life
Table 14.8 Next Generation Sequencing Kits: Distribution by Type of Sequencing
Table 14.9 Next Generation Sequencing Kits: Type of Sequencing Platform Used
Table 14.10 Next Generation Sequencing Kit Providers: Distribution by Year of Establishment
Table 14.11 Next Generation Sequencing Kit Providers: Distribution by Company Size
Table 14.12 Next Generation Sequencing Kit Providers: Distribution by Location of Headquarters
Table 14.13 Leading Players: Distribution by Number of Products
Table 14.14 Agilent Technologies: Annual Revenues, 2016-9M 2021 (USD Billion)
Table 14.15 PerkinElmer: Annual Revenues, 2016-H1 2021 (USD Billion)
Table 14.16 Thermo Fisher Scientific: Annual Revenues, 2016-H1 2021 (USD Billion)
Table 14.17 Abcam: Annual Revenues, FY 2016-H1 2021 (GBP Million)
Table 14.18 Roche: Annual Revenues, 2016-H1 2021 (CHF Billion)
Table 14.19 Tecan: Annual Revenues, 2016-H1 2021 (CHF Million)
Table 14.20 Takara Bio: Annual Revenues, FY 2016-Q1 2021 (JPY Billion)
Table 14.21 Patent Analysis: Distribution by Type of Patent
Table 14.22 Patent Analysis: Distribution by Year of Publication
Table 14.23 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Table 14.24 Patent Analysis: Distribution by Location of Jurisdiction (Country-wise)
Table 14.25 Patent Analysis: Distribution by CPC Symbols
Table 14.26 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 14.27 Leading Industry Players: Distribution by Number of Patents
Table 14.28 Leading Non-Industry Players: Distribution by Number of Patents
Table 14.29 Leading Patent Assignees: Distribution by Number of Patents
Table 14.30 Patent Analysis: Distribution by Age
Table 14.31 Patent Analysis: Patent Valuation
Table 14.32 Global Next Generation Sequencing Kits Market, 2021-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.33 Next Generation Sequencing Kits Market, 2021 and 2035: Distribution by Type of Nucleotide Sequenced (USD Billion)
Table 14.34 Next Generation Sequencing Kits Market for DNA, 2021-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.35 Next Generation Sequencing Market for RNA, 2021-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.36 Next Generation Sequencing Kits Market, 2021 and 2035: Distribution by Type of End User (USD Billion)
Table 14.37 Next Generation Sequencing Kits Market for Academic and Research Institutes, 2021-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.38 Next Generation Sequencing Kits Market for Pharmaceutical and Biotechnology Companies, 2021-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.39 Next Generation Sequencing Kits Market for Hospitals and Clinics, 2021-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.40 Next Generation Sequencing Kits Market for Others, 2021-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.41 Next Generation Sequencing Kits, 2021 and 2035: Distribution by Geography (USD Billion)
Table 14.42 Next Generation Sequencing Kits Market in North America, 2021-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.43 Next Generation Sequencing Kits Market in Europe, 2021-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.44 Next Generation Sequencing Kits Market in Asia-Pacific, 2021-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.45 Next Generation Sequencing Kits Market in Middle East and North Africa, 2021-2035: Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.46 Next Generation Sequencing Kits Market in Latin America, 2021-2035 : Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.47 Next Generation Sequencing Kits Market in Rest of the World, 2021-2035 : Conservative, Base and Optimistic Scenarios (USD Billion)
Table 14.48 Next Generation Sequencing Technologies: Analysis by Type of Application
Table 14.49 Next Generation Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
Table 14.50 Next Generation Sequencing Service Providers (Industry Players): Distribution by Company Size
Table 14.51 Next Generation Sequencing Service Providers (Industry Players): Distribution by Location of Headquarters
Table 14.52 Next Generation Sequencing Service Providers (Industry Players): Distribution by Type of Service Offered
Table 14.53 Next Generation Sequencing Service Providers (Non-Industry Players): Distribution by Year of Establishment
Table 14.54 Next Generation Sequencing Service Providers (Non-Industry Players): Distribution by Location of Headquarters
Table 14.55 Next Generation Sequencing Service Providers (Non-Industry Players): Distribution by Type of Service Offered

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 10x Genomics
  2. 1st BASE
  3. Abcam
  4. ABclonal 
  5. Advanced Biological Laboratories (ABL)
  6. Active Motif
  7. Admera Health
  8. Agendia
  9. Agilent Technologies
  10. Agiomix
  11. AgriGenome Labs 
  12. Almac Group
  13. Annoroad Gene Technology
  14. ANTISEL
  15. Applied Biological Materials (abm)
  16. Arizona Genomics Institute
  17. Auragen
  18. Australian Genome Research Facility (AGRF)
  19. BD
  20. BGI Genomics
  21. BioChain
  22. BioDynami
  23. Biofidal
  24. Bio-Rad
  25. Biosearch Technologies (Acquired by LGC)
  26. Brigham and Women's Hospital
  27. Brigham Young University
  28. Broad Institute
  29. CD Genomics
  30. CeGaT
  31. Cellecta
  32. CEN4GEN
  33. CENTOGENE
  34. Centre for Cellular and Molecular Platforms (C-CAMP)
  35. Children's Hospital of Philadelphia
  36. City of Hope
  37. Claret Bioscience
  38. Cold Spring Harbor Laboratory
  39. Columbia Genome Center
  40. Creative Biogene
  41. Dana-Farber Cancer Institute
  42. Dante Labs
  43. De Novo Genomics
  44. Devyser
  45. DiaCarta
  46. Diagenode (Acquired by Hologic)
  47. Diagnomics
  48. Diversigen
  49. DNA Genotek
  50. DNA Link
  51. DNAVision
  52. Durham University
  53. Earlham Institute
  54. Eclipse Bioinnovations
  55. Edinburgh Genomics
  56. Enzo Life Sciences
  57. Enzynomics
  58. EpiGentek
  59. Eurofins Genomics
  60. Fasteris
  61. Firalis 
  62. Fluidigm
  63. Fulgent Genetics
  64. Full Genomes Corporation (FGC)
  65. Garvan Institute of Medical Research
  66. Genapsys
  67. Gencove
  68. Gene by Gene
  69. GeneFirst
  70. GENEWIZ
  71. Genome.One
  72. GenomeScan
  73. GenomeStream
  74. Genomics Personalized Health
  75. Genomix4Life
  76. Genosity
  77. Genotypic Technology
  78. GenScript
  79. Genuity Science (Previously known as WuXi NextCODE)
  80. GenXPro
  81. Guardant Health
  82. Harvard College
  83. HistoGenetics
  84. Icahn Institute for Data Science and Genomic Technology
  85. Integrated DNA Technologies
  86. Illinois Institute of Technology
  87. Illumina
  88. Immatics Biotechnologies
  89. Intact Genomics
  90. Johns Hopkins University
  91. Leland Stanford Junior University
  92. Lexogen 
  93. LGC
  94. Loop Genomics
  95. Lucigen (Acquired by LGC)
  96. Macrogen
  97. MagBio Genomics
  98. Maryland Genomics
  99. Massachusetts General Hospital
  100. Massachusetts Institute of Technology
  101. Massey University
  102. Mass General Brigham (Previously known as Partners HealthCare)
  103. Max Planck Institute 
  104. McGill University
  105. Molecular Cloning Laboratories (MCLAB)
  106. MedGenome
  107. Merck
  108. MGI
  109. Microsynth
  110. MNG Laboratories (Acquired by LabCorp)
  111. MOgene
  112. myGenomics
  113. Natera
  114. National Institute of Health and Medical Research (INSERM)
  115. National Instrumentation Center for Environmental Management
  116. New England Biolabs (NEB)
  117. New York Genome Center (NYGC)
  118. NimaGen
  119. Norgen Biotek
  120. Novogene 
  121. Nucleome Informatics
  122. OGT
  123. Oklahoma Medical Research Foundation (OMRF)
  124. Omega Bioservices
  125. Otogenetics
  126. Oxford Nanopore Technologies
  127. Pacific Biosciences (PacBio)
  128. PerkinElmer 
  129. Phalanx Biotech 
  130. Psomagen
  131. Q2 Solutions
  132. QIAGEN
  133. Quantabio
  134. Quick Biology
  135. Rapid Genomics
  136. RealSeq Biosciences
  137. REPROCELL
  138. Roche
  139. RTL Genomics
  140. SeqLL
  141. SeqMatic
  142. Shanghai Oe Biotech
  143. Source BioScience
  144. Stanford University
  145. StarSEQ
  146. Swift Biosciences (Acquired by IDT)
  147. System Biosciences (SBI)
  148. Takara Bio
  149. Tecan
  150. Tempus
  151. Texas A&M AgriLife
  152. The Sequencing Center
  153. Theragen Etex
  154. Thermo Fisher Scientific
  155. The University of Edinburgh
  156. TIANGEN Biotech
  157. TransGen Biotech
  158. TriLink BioTechnologies
  159. Twist Bioscience
  160. UCLA Health
  161. University of California
  162. University of Delaware
  163. University of Leeds
  164. University of Liverpool
  165. University of Maryland
  166. University of Minnesota
  167. University of Oxford 
  168. University of Texas
  169. University of Washington
  170. University of Wisconsin
  171. University of Zurich
  172. UNSW Sydney
  173. Uppsala University
  174. Vazyme Biotech
  175. Veritas
  176. Verogen
  177. Waksman Institute of Microbiology (Rutgers University)
  178. Washington State University
  179. Washington University
  180. Wuhan Fraser Gene Information 
  181. Xcelris Genomics
  182. Yaazh Xenomics
  183. Yale School of Medicine
  184. YouSeq
  185. Zymo Research

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com